Disc Medicine, Inc. 4

Disc Medicine CEO John D. Quisel exercised 33,000 stock options and sold 33,000 shares of common stock on July 13, 2026 under a Rule 10b5-1 trading plan, with sale proceeds of about $2.46 million.

On July 13, 2026, Disc Medicine, Inc. CEO John D. Quisel exercised two stock option grants for a total of 33,000 shares of common stock (25,584 shares at a $9.86 strike and 7,416 shares at a $13.50 strike) and, on the same day, sold an aggregate 33,000 shares in three open-market transactions under a Rule 10b5-1 trading plan. The option exercises were reported at $0 in Column 4 as standard for Form 4 (strike prices are disclosed separately), implying gross exercise costs of approximately $252,266 for the 9.86-strike options and $100,116 for the 13.50-strike options. The corresponding sales consisted of 9,704 shares at a weighted average price of $74.2729, 16,896 shares at a weighted average price of $74.9469, and 6,400 shares at a weighted average price of $76.0520, for total sale proceeds of roughly $2.46 million. After these transactions, Quisel reported direct ownership of 226,064 shares of Disc Medicine common stock, which, using the sale prices as a proxy for market value, is worth approximately $16.8–$17.2 million, indicating a significant remaining stake despite the sizable, pre-planned liquidity event.

Filing Facts

CIK

1816736

Ticker

IRON

Form

4

Source Type

fda

Accession

0001193125-26-303535

Alert Tier

7